Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795639 · ClinicalTrials.gov registry record · Phase 3
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 183
- Enrollment target
NCT00795639 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 183 participants.
The verdict
NCT00795639, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 183 participants
- Enrollment target
Study Summary
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
Interventions
- DRUG Placebo
- DRUG Sitaxsentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795639
The ClinicalTrials.gov registry entry for NCT00795639 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00795639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795639 about?
NCT00795639 is a clinical study titled "Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)". This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
What is the current status of trial NCT00795639?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2008-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00795639?
The interventions under investigation include: Placebo (DRUG), Sitaxsentan (DRUG).
Who is sponsoring clinical trial NCT00795639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.